Deciphering the A–T+ enigma: Clinical relevance or diagnostic noise?
- 13 August 2025
- journal article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (4) , 1404-1405
Abstract
A recent Danish memory clinic cohort study sheds light on the enigmatic A–T+ biomarker profile – defined by elevated CSF p-tau181 in the absence of amyloid pathology. This commentary explores the clinical and conceptual implications of A–T+, arguing that it reflects a heterogeneous, non-Alzheimer group and highlighting the need to rethink A–T+ within a broader neurobiological framework. A–T+ is not diagnostic noise, but a call to investigate diverse pathways of neurodegeneration beyond amyloid-tau paradigms.Keywords
This publication has 7 references indexed in Scilit:
- Isolated elevation of 181p-tau in the cerebrospinal fluid is associated with distinct clinical features: Findings from a Danish memory clinic cohortJournal of Alzheimer’s Disease, 2025
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- The clinical importance of suspected non-Alzheimer disease pathophysiologyNature Reviews Neurology, 2024
- Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β PositivityJAMA Neurology, 2023
- Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer DiseaseJAMA Neurology, 2023
- Predictive value of phospho-tau/total-tau ratio in amyloid-negative Mild Cognitive ImpairmentNeuroscience Letters, 2022
- A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkersNeurology, 2016